Review article: Anthranoid laxatives and their potential carcinogenic effects

Alimentary Pharmacology and Therapeutics

Volumn 13, Issue 4, 1999, Pages 443-452

  Van Gorkom, B A P ^a   De Vries, E G E ^a   Karrenbeld, A ^a   Kleibeuker, J H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRANOID LAXATIVE; ANTHRAQUINONE; LAXATIVE; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CANCER RISK; CARCINOGENESIS; CARCINOGENIC ACTIVITY; CELL DAMAGE; COLON MUCOSA; COLORECTAL CARCINOMA; DRUG ABUSE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSEUDOMELANOSIS COLI; RAT; REVIEW;

ANIMALS; ANTHRAQUINONES; CARCINOGENS; CASSIA; CATHARTICS; COLONIC NEOPLASMS; HUMANS; PLANTS, MEDICINAL; PLANTS, TOXIC; RHAMNUS; RISK FACTORS;

EID: 0032891538     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1999.00468.x     Document Type: Review

References (107)

1. Franz G. The senna drug and its chemistry. Pharmacol 1993; 47(Suppl. 1): 2-6.
2. Brown JP. A review of the genetic effects of naturally occurring flavonoids, anthraquinones and related compounds. Mutation Res 1980; 75: 243-77.
3. Van Os FHL. Anthraquinone derivatives in vegetable laxatives. Pharmacol 1976; 14(Suppl. 1): 7-17.
4. De Witte P. Metabolism and pharmacokinetics of anthranoids. Pharmacol 1993; 47(Suppl. 1): 86-97.
5. Lemli J. Metabolism of sennosides - An overview. Pharmacol 1988; 36(Suppl. 1): 126-8.
6. Dreessen M, Eyssen H, Lemli J. The metabolism of sennosides A and B by the intestinal microflora: In vitro and in vivo studies on the rat and the mouse. J Pharm Pharmacol 1981; 33: 679-81.
7. De Witte P, Lemli L. The metabolism of anthranoid laxatives. Hepatogastroenterol 1990; 37: 601-5.
8. 2 synthesis and water and electrolyte secretion by senna anthraquinones is inhibited by indomethacin. J Pharm Pharmacol 1985; 37: 248-51.
9. Lemli J, Lemmens L. Metabolism of sennosides and rhein in the rat. Pharmacol 1980: 20(Suppl. 1): 50-7.
10. Breimer DD, Baars AJ. Pharmacokinetics and metabolism of anthraquinone laxatives. Pharmacol 1976; 14(Suppl. 1): 30-47.
11. Gaginella TS, Bass P. Laxatives: An update on mechanism of action. Life Sci 1978; 23: 1001-10.
12. Moreau JP, Moreau S, Skinner S. Comparative physiological disposition of some anthraquinone glycosides and aglycones. Biopharm Drug Disp 1985; 6: 325-34.
13. Leng-Peschlow E. Dual effect of orally administered sennasides on large intestine transit and fluid absorption in the rat. J Pharm Pharmacol 1986; 38: 606-10.
14. Ewe K. Effect of rhein on the transport of electrolytes, water and carbohydrates in the human jejunum and colon. Pharmacol 1980; 20(Suppl. 1): 27-35.
15. Wanitschke R. Influence of rhein on electrolyte and water transfer in the isolated rat colonic mucosa. Pharmacol 1980; 20(Suppl. 1): 21-6.
16. Percy WH, Burton MB, Fallick F, Burakoff R. A comparison in vitro of human and rabbit distal colonic muscle responses to inflammatory mediators. Gastroenterology 1990; 99: 1324-32.
17. Van der Ohe MR, Camilleri M, Kvols LK, Thomforde GM. Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea. N Engl J Med 1993; 329: 1073-8.
18. Nijs G, De Witte P, Geboes K, Lemli J. Influence of rhein anthrone and rhein on small intestine transit in rats; evidence of prostaglandin mediation. Eur J Pharmacol 1992; 218: 199-203.
19. Yagi T, Miyawaki Y, Nishikawa T, Yamauchi K, Kuwano S. Involvement of prostaglandin E-like material in the propulsive action of rhein anthrone, the intraluminal active metabolite of sennosides A and B in mice. J Pharm Pharmacol 1988; 40: 27-30.
20. Leng-Peschlow E. Acceleration of large intestine transit time in rats by sennosides and related compounds. J Pharm Pharmacol 1986; 38: 369-73.
21. 2α on small intestinal function in man. Nature 1973; 243: 169-71.
22. Nijs G, De Witte P, Van Hoestenberghe A, Geboes K, Lemli J. Direct and indirect evidence for the involvement of prostaglandins in the secretagogue action of rhein anthrone in the small intestine. Acta Gastroenterol Belg 1991; 54: 184-90.
23. Beubler E, Kollar G. Prostaglandin-mediated action of sennosides. Pharmacol 1988; 36(Suppl. 1): 85-91.
24. 2. Gut 1975; 16: 42-6.
25. Van Hoestenberghe A, De Witte P, Geboes K, Eyssen H, Nijs G, Lemli J. The effect of rhein and rhein anthrone on intestinal fluid transport and on large intestine transit in germ-free rats. Eur J Pharmacol 1992; 212: 121-3.
26. Verhaeren EHC. Mitochondrial uncoupling activity as a possible base for a laxative and antipsoriatic effect. Pharmacol 1980; 20(Suppl. 1): 43-9.
27. Verhaeren EHC. The uncoupling activity of substituted anthracene derivatives on isolated mitochondria from Phaseolus aureus. Phytochem 1980; 19: 501-3.
28. +-ATPase and permeability in vitro. Pharmacol 1988; 36(Suppl. 1): 98-103.
29. Philips RA, Love AH, Mitchell TG, Neptune EM Jr. Cathartics and the sodium pump. Nature 1965; 206: 1367-8.
30. +) adenosine triphosphatase. Biochem Pharmacol 1968; 17: 1207-12.
31. + across the cell membrane. Physiol Rev 1965; 45: 596-617.
32. Clauss W, Domokos G, Leng-Peschlow E. Effect of rhein on electrogenic chloride secretion in rabbit distal colon. Pharmacol 1988; 36(Suppl. 1): 104-10.
33. Goerg KJ, Wanitschke R, Schwarz M, Meyer zum Büschenfelde KH. Rhein stimulates active chloride secretion in the short-circuited rat colonic mucosa. Pharmacol 1988; 36(Suppl. 1): 111-19.
34. Nell G, Forth W, Rummel W, Wanitschke R. Pathway of sodium moving form blood to intestinal lumen under the influence of oxyphenisatin and deoxycholate. Arch Pharmacol 1976; 293: 31-47.
35. Ewe K. The physiological basis of laxative action. Pharmacol 1980; 20(Suppl. 1): 2-20.
36. Wanitschke R, Nell G, Rummel W. Influence of hydrostatic pressure gradients on net transfer of sodium and water across isolated rat colonic mucosa. Arch Pharmacol 1977; 297: 191-4.
37. Van Gorkom BAP, Karrenbeld A, Limburg AJ, Kleibeuker JH. The effect of sennosides on colonic mucosal histology and bowel preparation. Z Gastroenterol 1998; 36: 13-18.
38. Cooke WT. Laxative abuse. Acta Gastroenterol Belg 1981; 44: 448-58.
39. May H. Missbrauch von Abführmitteln, nachweisbare Schäden an Kolon, Anus und Stoffwechsel. Ärztezeitschr Naturheilverf 1982; 7: 365-71.
40. Cummings JH. Laxative abuse. Gut 1974; 15: 758-66.
41. Rawson MD. Cathartic colon. Lancet 1966; i: 1121-4.
42. Marshak RH, Gerson A. Cathartic colon. Am J Dig Dis 1960; 5: 724-7.
43. Avery-Jones F. Cathartic colon. Proc Roy Soc Med 1967; 60: 503-4.
44. Smith B. Effect of irritant purgatives on the myenteric plexus in man and the mouse. Gut 1968; 9: 139-43.
45. Smith B. Pathologic changes in the colon produced by anthraquinone purgatives. Dis Colon Rectum 1973; 16: 455-8.
46. Kiernan JA, Heinicke EA. Sennosides do not kill myenteric neurons in the colon of the rat or mouse. Neuroscience 1989; 30: 837-42.
47. Dufour P, Gendre P. Ultrastructure of mouse intestinal mucosa and changes observed after long term anthraquinone administration. Gut 1984; 25: 1358-63.
48. Speare GS. Melanosis coli: Experimental observations on its production and elimination in 23 cases. Am J Surg 1951; 82: 631-7.
49. Bockus HI, Willard JH, Banks J. Melanosis coli. The ethiologic significance of the anthracene laxatives: A report of forty-one cases. J Am Med Assoc 1933; 101: 1-6.
50. Steer HW, Colin-Jones DG. Melanosis coli: Studies of the toxic effect of irritant purgatives. J Pathol 1975; 115: 199-205.
51. Zobel AJ, Susnow DA. Melanosis coli; its clinical significance. Arch Surg 1935; 30: 974-9.
52. Wittoesch JH, Jackman RJ, McDonald JR. Melanosis coli; general review and a study of 887 cases. Dis Colon Rectum 1958; 1: 172-80.
53. Badiali D, Marcheggiano A, Pallone F, et al. Melanosis of the rectum in patients with chronic constipation. Dis Colon Rectum 1985; 28: 241-5.
54. Leng-Peschlow E. Senna and pseudomelanosis coli. Pharmacol 1992; 44(Suppl. 1): 33-5.
55. Byers RJ, Marsh P, Parkinson D, Haboubi NY. Melanosis coli is associated with an increase in colonic epithelial apoptosis and not with laxative use. Histopathology 1997; 30: 160-4.
56. Marshall JB, Singh R, Diaz-Arias AA. Chronic unexplained diarrhoea: Are biopsics necessary if colonoscopy is normal. Am J Gastroenterol 1995; 90: 372-6.
57. Müller-Lissner S. Nebenwirkungen von Laxantien. Z Gastroenterol 1992; 30: 418-27.
58. Walker NI, Bennett RE, Axelsen RA. Melanosis coli. A consequence of anthraquinone-induced apoptosis of colonic epithelial cells. Am J Pathol 1988; 131: 465-76.
59. Morgenstern L, Shemen L, Allen W, Amodeo P, Michel SL. Melanosis coli. Changes in appearance when associated with colonic neoplasia. Arch Surg 1983; 118: 62-4.
60. Koskela E, Kulju T, Collan Y. Melanosis coli. Prevalence, distribution and histologic features in 200 consecutive autopsies at Kuopio University Central Hospital. Dis Colon Rectum 1989; 32: 235-9.
61. Lubarsch O. Über das sogennante Lipofuschin. Virchows Archiv Pathol Anat 1922; 239: 491-503.
62. Pick L, Brahn B. Das Pigment der melanosis coli und seine chemische Darstellung aus dem Organ. Virchows Archiv Pathol Anat 1930; 275: 37-49.
63. Ghadially FN, Parry EW. An electron-microscope and histochemical study of melanosis coli. J Pathol Bacteriol 1966; 92: 313-7.
64. Schrodt GR. Melanosis coli: A study with the electron microscope. Dis Colon Rectum 1963; 6: 277-83.
65. Kerr JFR, Wyllie AH, Currie AR. Apoptosis; a basic biological phenomenon with wide ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239-57.
66. Wyllie AH, Kerr JFR, Currie AR. Cell death; the significance of apoptosis. Int Rev Cytol 1980; 68: 251-306.
67. Walker NI, Smith MM, Smithers BM. Ultrastructure of human melanosis coli with reference to its pathogenesis. Pathology 1993; 25: 120-3.
68. Siegers CP, Von Hertzberg-Lottin E, Otte M, Schneider B, Antranoid laxative abuse - A risk for colorectal cancer? Gut 1993; 34: 1099-101.
69. Swanbeck G, Zetterberg G. Studies on dithranol and dithranol-like compounds: I. Binding to nucleic acids. Acta Derm Venereol 1971; 51: 41-4.
70. Westendorf J, Marquardt H, Poginsky B, Dominiak M, Schmidt J, Marquardt H. Genotoxicity of naturally occurring hydroxyanthraquinones. Mutat Res 1990; 240: 1-12.
71. Kawai K, Mori H, Sugie S, et al. Genotoxicity in the hepatocyte/DNA repair test and toxicity to liver mitochondria of 1-hydroxyanthraquinone and several dihydroxyanthraquinones. Cell Biol Toxicol 1986; 2: 457-68.
72. Wölfle D, Schmutte C, Westendorf J, Marquardt H. Hydroxyanthraquinones as tumor promoters: Enhancement of malignant transformation of C3H mouse fibroblasts and growth stimulation of primary rat hepatocytes. Cancer Res 1990; 50: 6540-4.
73. Brown JP, Brown RJ. Mutagenesis by 9,10-anthraquinone derivatives and related compounds in Salmonella Typhimurium. Mutat Res 1976 40: 203-224.
74. Bruggeman IM, Van der Hoeven JCM. Lack of activity of the bacterial mutagen emodin in HGPRT and SCE assay with V79 Chinese hamster cells. Mutat Res 1984; 138: 219-24.
75. Masuda T, Haraikawa K, Morooka N, Nakano S, Ueno Y. 2-Hydroxyemodin, an active metabolite of emodin in the hepatic microsomes of rats. Mutat Res 1985; 149: 327-52.
76. Tikkanen L, Matsushima T, Natori S. Mutagenicity of anthraquinones in the Salmonella preincubation test. Mutat Res 1983; 116: 297-304.
77. Brown JP, Dietrich PS. Mutagenicity of anthraquinone and benzanthrone derivatives in the Salmonella/microsome test: Activation of anthraquinone glycosides by enzymic extracts of rat cecal bacteria. Mutat Res 1979; 66: 9-24.
78. Ames BN, McCann J, Yamasaki E. Methods for dctecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test. Mutat Res 1975; 31: 347-64.
79. Mengs U. Toxic effects of sennosides in laboratory animals and in vitro. Pharmacol 1988; 36(Suppl. 1): 180-7.
80. Morimoto I, Watanabe F, Osawa T, Okitsu T, Kada T. Mutagenicity screening of crude drugs with Bacillus subtilis recassay and Salmonella/microsome reversion assay. Mutat Res 1982; 97: 81-102.
81. Sandnes D, Johansen T, Teien G, Ulsaker G. Mutagenicity of crude senna and senna glycosides in Salmonella Typhimurium. Pharmacol Toxicol 1992; 71: 165-72.
82. Lydén-Sokolowski A, Nilsson A, Sjöberg P. Two-year carcinogenicity study with sennosides in the rat: Emphasis on gastro-intestinal alterations. Pharmacol 1993; 47(Suppl. 1): 209-15.
83. Mori H, Yoshimi N, Iwata H, et al. Carcinogenicity of naturally occurring 1-hydroxyanthraquinone in rats: Induction of large bowel, liver and stomach neoplasms. Carcinogenesis 1990; 11: 799-802.
84. Mori H, Sugie S, Niwa K, Takahashi M, Kawai K. Induction of intestinal tumours in rats by chrysazin. Br J Cancer 1985; 52: 781-3.
85. Mori H, Sugie S, Niwa K, Yoshimi N, Tanaka T, Hirono I. Carcinogenicity of chrysazin in large intestine and liver of mice. Jpn J Cancer Res 1986; 77: 871-6.
86. Toyoda K, Nishikawa A, Furukawa F, Kawanishi T, Hayashi Y, Takahashi M. Cell proliferation induced by laxatives and related compounds in the rat intestine. Cancer Lett 1994; 83: 43-9.
87. Mori H, Mori Y, Tanaka T, et al. Cell kinetic analysis of the mucosa epithelium and assay of ornithine decarboxylase activity during the process of 1-hydroxyanthraquinone-induced large bowel carcinogenesis in rats. Carcinogenesis 1992; 13: 2217-20.
88. Mori Y, Yoshimi N, Iwata H, Tanaka T, Mori H. The synergistic effect of 1-hydroxyanthraquinone on methylazoxymethanol acetate-induced carcinogenesis in rats. Carcinogenesis 1991; 12: 335-8.
89. Moreto E, Ghia M, Brambilla G. Evaluation of the potential carcinogenic activity of senna and cascara glycosides for the rat colon. Cancer Lett 1996; 101: 79-83.
90. Magnuson BA, Carr I, Bird RP. Ability of aberrant crypt foci characteristics to predict colon tumor incidence in rats fed cholic acid. Cancer Res 1993; 53: 4499-504.
91. Wargovich MJ, Goldberg MT, Newmark HL, Bruce WR. Nuclear aberrations as a short-term test for genotoxicity to the colon: Evaluation of nineteen agents in mice. J Natl Cancer Inst 1983; 71: 133-7.
92. Ronen A, Heddle JA. Site-specific induction of nuclear anomalies (apoptotic bodies and micronuclei) by carcinogens in mice. Cancer Res 1984; 44: 1536-40.
93. Mengs U, Rudolph RL. Light and electron-microscopic changes in the colon of the guinea pig after treatment with anthranoid and non-anthranoid laxatives. Pharmacol 1993; 47(Suppl. 1): 172-7.
94. Boyd JT, Doll R. Gastro-intestinal cancer and use of liquid paraffin. Br J Cancer 1954; 8: 231-7.
95. Nakamura GJ, Schneiderman LJ, Klauber MR. Colorectal cancer and bowel habits. Cancer 1984; 54: 1475-7.
96. Gardiner JS, Walker SA, Maclean AJ. A retrospective mortality study of substituted anthraquinone dyestuff workers. Br J Indust Med 1982; 39: 355-60.
97. Kune GA, Kune S, Field B, Watson LF. The role of chronic constipation, diarrhea, and laxative use in the etiology of large-bowel cancer. Data from the melbourne colorectal cancer study. Dis Colon Rectum 1988; 31: 507-12.
98. Burkitt DP. Epidemiology of cancer of the colon and rectum. Cancer 1971; 28: 3-13.
99. Burkitt DP, Walker ARP, Painter NS. Effect of dietary fibre on stools and transit-times and its role in the causation of disease. Lancet 1972; ii: 1408-14.
100. Papadimitriou C, Day N, Tzonou A, Gerovassilis F, Manousos O, Trichopoulos D. Biosocial correlates of colorectal cancer in Greece. Int J Epidemiol 1984; 13: 155-9.
101. Higginson J. Etiological factors in gastrointestinal cancer in man. J Natl Cancer Inst 1966; 37: 527-45.
102. Patel PM, Selby PJ, Deacon J, Chilvers C, McElwain TJ. Anthraquinone laxatives and human cancer: An association in one case. Postgrad Med J 1989; 65: 216-17.
103. Nusko G, Schneider B, Muller G, Kusche J, Hahn EG. Retrospective study on laxative use and melanosis coli as risk factors for colorectal neoplasia. Pharmacol 1993; 47(Suppl. 1): 234-41.
104. Steward MJ, Hickman EM. Observations on melanosis coli. J Pathol Bact 1931; 34: 61-72.
105. Kleibeuker JH. Cats A, Zwart N, Mulder NH, Hardonk MJ. De Vries EGE. Excessively high cell proliferation in sigmoid colon after an oral purge with anthraquinone glycosides. J Natl Cancer Inst 1995; 87: 452-3.
106. Van Gorkom BAP, Karrenbeld A, Koudstaal J, De Vries EGE, Kleibeuker JH. Effects of sennosides on colonic epithelial cell proliferation and bcl-2 gene expression: Possible mechanisms for carcinogenic effects. Gastroenterology 1996; 110: A608(Abstract).
107. Konstantakos AK, Siu I-M, Pretlow TG, Stellato TA, Pretlow TP. Human aberrant crypt foci with carcinoma in situ from a patient with sporadic colon cancer. Gastroenterology 1996; 111: 772-7.